Skip to main content
. Author manuscript; available in PMC: 2022 Jan 27.
Published in final edited form as: Adv Funct Mater. 2020 Oct 13;31(5):2007096. doi: 10.1002/adfm.202007096

Figure 8.

Figure 8.

LCP delivers tumor antigen MUC1 mRNA in combination with anti-CTLA-4 mAb to treat melanoma. a) Schematic illustration of LCP (MUC1 mRNA) enhancing tumor antigen presentation and anti-CTLA-4 mAb blocking an immune checkpoint to activate T cell-mediated tumor killing. b) Tumor growth inhibition experiment. c) Flow cytometry analysis of CD8+ T cells in tumors. Adapted with permission.[188] Copyright 2018, Elsevier.